mardi 14 juin 2016

Onco Actu du 14 juin 2016

2. Etiologie

Inherited mutation doubles the risk of death from malignant melanoma [arolinska Institutet]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical cancer cases to rise sharply in the elderly, charity warns [PharmaTimes]

5. Traitements

New research provides hope for patients with hard-to-treat breast cancer [Cancer Research UK]

5.10 Traitements - Essais

More clinical trials are succeeding for the first time in years [STAT]

5.12 Immunothérapies

Alpine Immune Sciences, Former Dendreon CEO’s Latest Startup, Gets $48M [Xconomy]

Former Dendreon CEO Secures $48M For Cancer Immunotherapy Startup [Forbes]

5.2 Pharma

Novartis, Colombia face off over cancer drug cost [STAT]

5.3 Traitements - FDA, EMA,...

EMA celebrates ten years of its patients and consumers working party [EMA]

5.4 Traitements - Economie

Cancer Drugs Can't Stay This Expensive Forever [Bloomberg]

5.6 ESMO

ESMO 2016 Media Alert: From Disease Treatment to Patient Care [ESMO]

5.9.3 EHA

Antibody-based drug helps “bridge” leukemia patients to curative treatment [MD Anderson Cancer Center]

Killer antibodies against AML [European Hematology Association]

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients [European Hematology Association]

Novartis’ Jakavi comes out on top in rare blood cancer trial [PharmaTimes]

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 PACE Clinical Trial [ARIAD Pharmaceuticals]

6. Lutte contre les cancers

Cancer Groups, Congress Push for Dedicated Cancer Center at FDA [The Cancer Letter]

6.1 Observation

Middle aged more likely to be diagnosed with advanced lung cancer [Cancer Research UK]

6.10 Politiques

Clinton vs. Trump: A race between a policy wonk and a ‘black box’ [STAT]

21st Century Cures Act nears passage with little news media scrutiny [HealthNewsReview]

6.6 Publications

Misidentified cell line fells cancer paper [Retraction Watch]